- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT02206555
PrEP Demonstration Project (PRELUDE Study) (PRELUDE)
Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project
Significant increases in HIV diagnoses among gay and other homosexually active men, in Australia and internationally, have been observed since the late 1990s. The levels of high HIV risk sexual practices among gay men have also increased, particularly unprotected anal intercourse (UAI). Nationally, over three quarters of the new HIV infections diagnosed annually are among men who have sex with men (MSM). The proportion of heterosexual men and women among those diagnosed with HIV annually has also increased in recent years. Despite successes in some situations, HIV transmission has not been adequately reduced by the prevention methods available to those at risk, such as education, condoms, and treatment of sexually transmitted infections (STIs).
The effectiveness of daily oral antiretroviral medications (ARVs) as preexposure prophylaxis of HIV (PrEP) has now been established by clinical trials in both heterosexual adults and homosexual men. Whether PrEP confers high rates of protection in real life situations and is a feasible strategy to implement still requires further investigation. Through its "HIV prevention strategy 2015: New era," NSW Health committed to consider how to most appropriately and efficiently implement PrEP in line with evidence. This commitment translated in the support to this PrEP demonstration project.
This demonstration project is designed to evaluate the off-label provision of daily combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known as TRUVADA) as PrEP to a sample of sero-negative individuals at high risk for HIV infection in clinical settings in New South Wales. The project will inform policy development regarding primary HIV prevention with PrEP.
This is an open-label, single-arm treatment evaluation study. All consenting and eligible HIV negative participants will receive TRUVADA prescribed for daily administration orally. At each followup visit, the following procedures will be conducted: clinical evaluations/ procedures, laboratory evaluations/ procedures, testing for HIV, STIs, hepatic and renal function, assessment for adherence to the prescribed medication, side effects, eligibility for next TRUVADA prescription, and willingness to continue on PrEP.
As a study requirement, participants will be offered a self-administered assessment of behaviour, lifestyle and attitudes which will be conducted ideally within two and no more than seven days of the clinic visit in the participant's private space.
Analyses will include: the feasibility of PrEP delivery, adherence to the study medication, safety and tolerability, the effects of PrEP use on behavior, and statistical analyses of the risk of HIV seroconversion.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 4. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
New South Wales
-
Camperdown, New South Wales, Ausztrália, 2050
- RPA Sexual Health
-
Darlinghurst, New South Wales, Ausztrália, 2010
- Holdsworth House Medical Practice
-
Darlinghurst, New South Wales, Ausztrália, 2010
- St Vincent's Hospital HIV, Immunology and Infectious Disease Unit
-
Parramatta, New South Wales, Ausztrália, 2150
- Western Sydney Sexual Health Centre
-
Sydney, New South Wales, Ausztrália, 2000
- Sydney Sexual Health Centre
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- HIV negative at enrollment (per algorithm provided in protocol)
- At high and ongoing risk for acquiring HIV infection (per algorithm provided in protocol)
- Aged 18 years or over
- Resident of NSW (or elsewhere in Australia if they visit NSW with sufficient frequency to allow participation)
- Medicare eligible (to have Medicare coverage for the standard-of-care services)
- Willing and able to provide informed consent
- Willing and able to take part in all required study procedures
- Proficiency in written and spoken English (necessary to complete attitude, behavioural and lifestyle surveys)
Exclusion Criteria:
- HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive status is not confirmed by testing, delay starting PrEP for at least one month and reconfirm negative HIV-1 status).
- Having an estimated creatinine clearance (glomerular filtration rate [GFR]) <60ml/min
- Having or developing clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort, and weakness)
- Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal anti-inflammatory drugs / NSAIDs)
- Allergic to tenofovir disoproxil fumarate and/or emtricitabine (based on self-report or recorded)
- Concurrently taking prescribed products containing emtricitabine or tenofovir disoproxil fumarate including ATRIPLA®, COMPLERA®, EMTRIVA, STRIBILD®, VIREAD; other drugs containing lamivudine; HEPSERA
- Mental health issues, memory loss or other cognitive impairment or intellectual disability that may compromise participant safety and/or regimen adherence
- Factors or conditions that may compromise a participant's retention in the study (incarceration, planned relocation or potential absence from NSW for a period of 3 months or longer during the course of the study)
- Unwilling to adhere to any of the required study procedures
- Currently breastfeeding
Note: Safety for infants exposed to TRUVADA during pregnancy is not fully assessed but no harm has been reported. Therefore, planning to become pregnant or currently being pregnant is not an exclusion criterion for this study. However, women who are pregnant should learn about the risks and benefits of TRUVADA to reduce the risk of acquiring HIV during their pregnancy. Site investigators will review the risks and benefits of TRUVADA and of potential HIV infection with pregnant women and women who plan to become pregnant.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Treatment group (TRUVADA)
Homosexual men and heterosexual men and women at high risk of HIV infection
|
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Time to accrual
Időkeret: Approximately 18 months
|
Time to accrual of 300 person-years of follow-up on TRUVADA.
Each participant will receive TRUVADA for a maximum of 12 months, and will be followed for an additional three months after discontinuation.
(Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
|
Approximately 18 months
|
Seroconversion-free time on PrEP
Időkeret: Approximately 18 months
|
Seroconversion-free time on PrEP (Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
|
Approximately 18 months
|
Time to TRUVADA discontinuation
Időkeret: Approximately 18 months
|
Time to TRUVADA discontinuation (primary endpoint: adherence)
|
Approximately 18 months
|
Prescribed doses taken
Időkeret: Approximately 18 months
|
Percentage of prescribed doses taken orally in the prescribed period (primary endpoint: adherence)
|
Approximately 18 months
|
Incidents of HIV seroconversion
Időkeret: Approximately 24 months
|
Incidence of HIV seroconversion among study participants during the course of their study participation and in six months following PrEP discontinuation (primary endpoint: safety and side effects)
|
Approximately 24 months
|
Incidents of rectal gonorrhea and chlamydia
Időkeret: Approximately 18 months
|
New rectal gonorrhoea and chlamydia infections (primary endpoint: behavioral effects of PrEP use)
|
Approximately 18 months
|
Serious adverse reactions
Időkeret: Approximately 18 months
|
(primary endpoint: safety and side effects)
|
Approximately 18 months
|
Adverse events
Időkeret: Approximately 18 months
|
Any adverse events leading to interruption or discontinuation of the study product (TRUVADA) (primary endpoint: safety and side effects)
|
Approximately 18 months
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi szék: Iryna Zablotska, MD, MPH, PhD, The Kirby Institute for Infection and Immunity in Society
Publikációk és hasznos linkek
Általános kiadványok
- Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, Foster R, Grulich AE, Zablotska IB; PRELUDE Study Team; NSW HIV Prevention Partnership Project. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. AIDS Behav. 2019 May;23(5):1287-1296. doi: 10.1007/s10461-018-2353-5.
- Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, Foster R, McNulty A, Grulich AE, Zablotska IB; PRELUDE Study Team. Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project. Front Public Health. 2017 Dec 15;5:341. doi: 10.3389/fpubh.2017.00341. eCollection 2017.
- Vaccher S, Grulich A, McAllister J, Templeton DJ, Bloch M, McNulty A, Holden J, Poynten IM, Prestage G, Zablotska I; PRELUDE Study Team. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open. 2016 Jun 20;6(6):e012179. doi: 10.1136/bmjopen-2016-012179. Erratum In: BMJ Open. 2016 Jun 27;6(6):e012179corr1.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- HEPP 1403
- 14/098 (Egyéb azonosító: St Vincent's Hospital HREC)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthToborzásHIV | HIV-tesztelés | HIV kapcsolat az ellátással | HIV kezelésEgyesült Államok
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationBefejezvePartner HIV-teszt | Páros HIV-tanácsadás | Párkapcsolat | HIV incidenciaKamerun, Dominikai Köztársaság, Grúzia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre... és más munkatársakIsmeretlenHIV | HIV-fertőzött gyermekek | HIV-fertőzésnek kitett gyermekekKamerun
-
University of MinnesotaVisszavontHIV fertőzések | HIV/AIDS | Hiv | AIDS | AIDS/HIV probléma | AIDS és fertőzésekEgyesült Államok
-
CDC FoundationGilead SciencesIsmeretlenHIV preexpozíciós profilaxis | HIV kemoprofilaxisEgyesült Államok
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... és más munkatársakToborzásHIV | HIV-tesztelés | Kapcsolat a gondozássalDél-Afrika
-
University of Maryland, BaltimoreVisszavontHiv | Veseátültetés | HIV-tározó | CCR5Egyesült Államok
-
University of WashingtonNational Institute of Mental Health (NIMH)ToborzásHIV megelőzés | HIV preexpozíciós profilaxis | VégrehajtásKenya
-
Hospital Clinic of BarcelonaBefejezveIntegráz inhibitorok, HIV; HIV PROTEÁZ INHIBSpanyolország
-
Erasmus Medical CenterMég nincs toborzásHIV fertőzések | Hiv | HIV-1 fertőzés | HIV I fertőzésHollandia
Klinikai vizsgálatok a emtricitabine/tenofovir disoproxil fumarate
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI 360; CONR...Aktív, nem toborzóAdherencia, gyógyszeres kezelés | Az egészségügyi ellátás elfogadhatóságaDél-Afrika, Zimbabwe
-
University of California, San DiegoAktív, nem toborzóHiv | HormonterápiaEgyesült Államok
-
Plan Nacional sobre el Sida (PNS)Effice Servicios Para la Investigacion S.L.BefejezveKoronavírus fertőzésSpanyolország
-
University of ChicagoPlanned Parenthood Great PlainsVisszavont
-
Public Health Foundation Enterprises, Inc.National Institute of Mental Health (NIMH); Emory University; San Francisco Department... és más munkatársakBefejezveKockázati magatartás | HIV megelőzés | Adherencia, gyógyszeres kezelés | Expozíció előtti profilaxisEgyesült Államok
-
Public Health Foundation Enterprises, Inc.National Institute of Mental Health (NIMH); Emory University; San Francisco Department... és más munkatársakBefejezveKockázati magatartás | HIV megelőzés | Adherencia, gyógyszeres kezelés | Expozíció előtti profilaxisEgyesült Államok
-
Public Health Foundation Enterprises, Inc.University of California, San Francisco; California HIV/AIDS Research Program; San... és más munkatársakBefejezveTransznemű személyek | Expozíció előtti profilaxisEgyesült Államok
-
Fundacion Clinic per a la Recerca BiomédicaBefejezve
-
University of Colorado, DenverBefejezveEgészséges önkéntesek | Farmakokinetika
-
National Center for Research Resources (NCRR)University of RochesterBefejezveMitokondriális myopathia